Finance entity
markets is the sole category represented across all 1 tracked stories. Olema Pharmaceuticals is most often covered alongside Cormorant Asset Management, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window.
Last mentioned: Mar 22, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
markets is the sole category represented across all 1 tracked stories. Olema Pharmaceuticals is most often covered alongside Cormorant Asset Management, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window. The 5 average consequence score is below the beat benchmark of 6.5 in the same window. We currently track 1 Finance story that mention Olema Pharmaceuticals, all published on March 22, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 71 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Olema Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Commercial Launch
Target date for the market entry of palazestrant for ER+ breast cancer treatment.
Institutional Stake Disclosure
Reports surfaced regarding a significant $122 million position held by a major investor.
Price Target Hike
Wall Street analysts raised the price target for OLMA to $62.00, citing clinical optimism.
Earnings & SEC Filing
Olema reported quarterly results and filed an 8-K detailing its financial condition.
Olema Pharmaceuticals (OLMA) has delivered a massive 242% return over the past year, fueled by clinical progress in its lead breast cancer candidate, palazestrant. A recent $122 million institutional position has sparked debate over whether the biotech firm still has significant room for growth ahead of a projected 2027 launch.
Source: finance.yahoo.com · fool.com
Olema Pharmaceuticals is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
